Daix (France), July eight, 2020 – Inventiva (Euronext Paris: IVA) (“ Inventiva “Or the” Society “), A biopharmaceutical firm specializing within the scientific improvement of small molecules administered orally for the therapy of nonalcoholic steatohepatitis (” NASH “), Mucopolysaccharidoses (” MPS “) And different ailments with important unmet medical want, broadcasts at present the formal begin of the process for constructing the order guide and the submitting of a” modification »(Endorsement) to the registration doc (Type F-1) to incorporate an indicative worth vary throughout the framework of its proposed supply, topic specifically to market circumstances, of a complete of seven,478,261 shares bizarre of the Firm. This supply challenge consists of a suggestion ofAmerican Depositary Shares (the ” ADS “), Every representing one frequent share in america (the” U.S. supply “) And a concurrent supply of frequent shares in sure nations exterior america (the” European supply “And collectively, the” World Supply “). Inventiva plans to grant the guaranteeing banks (” Guarantor Banks ») An over-allotment choice permitting them to subscribe for a interval of 30 days of ADS and / or extra bizarre shares as much as a restrict of 15% of the entire variety of ADS and bizarre shares issued throughout the framework of the Supply Total.
All securities bought underneath the World Supply will likely be issued by the Firm. The Firm has utilized to checklist its ADSs on the Nasdaq World Market underneath the image “IVA”. The frequent shares of the Firm are admitted to buying and selling on the regulated market of Euronext in Paris underneath the image “IVA”.
Jefferies LLC, Stifel, Nicolaus & Firm, Integrated and Guggenheim Securities, LLC act as world coordinators and affiliate bookkeepers of the World Supply. H.C. Wainwright & Co., LLC acts as lead and Roth Capital Companions, LLC and KBC Securities USA LLC act as related lead for the U.S. Supply
Namsen Capital acts as an advisor to Inventiva's capital markets.
The supply worth must be between $ 13.40 and $ 15.40 per ADS, or between € 11.84 and € 13.60 per frequent share (calculated utilizing the change fee as of July eight, 2020 of 1.00 euro = 1.1321 US ). The subscription worth per ADS in US and the corresponding subscription worth per bizarre share in euros, in addition to the ultimate variety of ADSs and bizarre shares issued throughout the framework of the World Supply, will likely be decided on the finish the method of constructing the order guide which begins instantly. The ultimate unit subscription worth for ADSs and bizarre shares will likely be not less than equal to the weighted common of the Firm's share costs on the regulated market of Euronext in Paris for the final three buying and selling periods previous the beginning of the supply (i.e. the periods of July 6, 7 and eight, 2020), presumably lowered by a most low cost of 10%.
As a sign, the completion of the World Supply would consequence, on the premise of the difficulty of a most of seven,478,261 bizarre shares (together with within the type of ADSs), a dilution of roughly 19.5% of the share capital of the Firm on an undiluted foundation (excluding the train of the Over-allotment Choice) and of roughly 21.eight% of the share capital of the Firm on an undiluted foundation (after full train of the over-allotment choice by the Guarantor Banks).
ADSs and / or bizarre shares will likely be issued via a capital improve with out preferential subscription rights for shareholders by the use of a suggestion to the general public, excluding the gives referred to in article L. 411-2, 1 ° of the Financial and Monetary Code and throughout the framework of the provisions of article L.225-136 of the Industrial Code and in accordance with 15th and 19th resolutions of the mixed basic assembly of shareholders of the Firm held on Could 28, 2020.
The ultimate variety of bizarre shares provided, together with the variety of bizarre shares provided within the type of ADS, and their subscription worth will likely be determined by the Chief Govt Officer of the Firm.
The Firm plans to announce the result of the World Supply as quickly as attainable in a press launch following the pricing.
The settlement-delivery of the US Supply and the settlement-delivery of the European Supply will happen concurrently and may happen on the third working day following the willpower of the ultimate subscription worth for the World Supply.
The Firm plans to make use of the web proceeds of the World Supply, along with the quantity of its accessible money, as follows (calculated on the premise of the change fee on July eight, 2020 of 1.00 euro = 1; 1321 US ):
- for roughly € 75 million (US $ 85 million) to finish preparations and launch a Section III scientific trial of lanifibranor within the therapy of NASH;
- for roughly € 26.5 million (or US $ 30 million) to finish a Section Ib / II scientific trial of odiparcil in a pediatric inhabitants with MPS VI, provoke an extension of the Section IIa trial d in sufferers over 16 years of age affected by MPS VI and launching the Section III scientific trial of odiparcil as monotherapy and together with enzyme substitute remedy in grownup sufferers and kids affected by MPS VI ;
- roughly $ Four.Four million (US $ 5 million) to advance program improvement within the Firm's Hippo signaling pathway and different pre-clinical applications; and
- for the stability, working capital and basic wants of the Firm.
The Firm estimates that the web proceeds of the World Supply, along with the quantity of its accessible money, will allow it to finance its working and funding bills, not less than till the fourth quarter of 2022.
The supply of securities referred to on this press launch will likely be made solely by a prospectus (F-1). Copies of stated preliminary prospectus (F-1) might be obtained from: Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by phone at 877-547-6340 or 877-821-7388, or by electronic mail at Prospectus_Department@Jefferies.com; Stifel, Nicolaus & Firm, Integrated, Consideration: Prospectus Division, One Montgomery Road, Suite 3700, San Francisco, CA 94104 or by cellphone at (415) 364-2720 or by electronic mail at syndprospectus@stifel.com , or Guggenheim Securities, LLC, Consideration: Fairness Syndicate Division, 330 Madison Avenue, eightth Flooring, New York, NY 10017, or by cellphone at 212-518-9544, or by electronic mail at GSEquityProspectusDelivery@guggenheimpartners.com
A registration declaration within the type of a Type F-1 relating to those securities has been filed with theU.S. Securities and Change Fee (SEC) however has not but taken impact. These securities can’t be bought and no subscription request might be accepted earlier than the registration declaration comes into drive. The registration assertion is publicly accessible from the SEC web site.
A request for admission of the bizarre shares issued throughout the framework of the World Supply will likely be made to the regulated market of Euronext in Paris in accordance with the admission prospectus which will likely be submitted for approval to the Autorité des Marchés Financiers (” AMF “) Comprising the 2019 Common Registration Doc of the Firm, filed with the AMF on June 19, 2020, underneath quantity D.20-0551 which contains by reference the 2019 annual monetary report, as supplemented by the modification audit Common Registration Doc which will likely be filed with the AMF on July 10, 2020, in addition to a Transaction Notice, together with a abstract of the prospectus. As of the submitting of the modification to stated Common Registration Doc with the AMF, copies of the 2019 Common Registration Doc, as amended, can be found freed from cost on the Firm's registered workplace positioned at 50 rue de Dijon, 21121 Daix, France, and might be consulted on its web site (www.inventivapharma.com) in addition to on the AMF web site (www.amf-france.org).
This press launch doesn’t represent a suggestion to promote or a solicitation of a suggestion to purchase securities in any jurisdiction, and might not be thought of as a suggestion, solicitation or sale in any jurisdiction inside which any supply, solicitation or sale can be unlawful earlier than registration or certification in accordance with native rules.
About Inventiva
Inventiva is a biopharmaceutical firm specializing within the scientific improvement of small molecules administered orally for the therapy of NASH, MPS and different ailments with important unmet medical want.
With its experience and important expertise within the improvement of compounds concentrating on nuclear receptors, transcription components and epigenetic modulation, Inventiva is presently growing two drug candidates, in addition to a big portfolio of a number of applications within the preclinical stage.
Lanifibranor, its most superior drug candidate, is presently underneath improvement for the therapy of sufferers with NASH, a standard continual and progressive liver illness, for which there’s presently no accredited therapy. Inventiva just lately printed optimistic outcomes from its Section IIb scientific research evaluating anifibranor for the therapy of sufferers with NASH.
Odiparcil is the second scientific candidate drug that Inventiva is growing for the therapy of sufferers with a subtype of MPS, a gaggle of uncommon genetic ailments. A Section I / II scientific trial in kids with MPS VI is being ready following the publication of the optimistic outcomes of the Section IIa scientific trial in grownup sufferers with the identical illness finish 2019.
In parallel, Inventiva is within the course of of choosing a candidate drug in oncology for its program within the Hippo signaling pathway. As well as, the Firm has entered right into a strategic partnership with AbbVie within the space of autoimmune ailments. AbbVie began scientific improvement of ABBV-157, a drug candidate for the therapy of the average to extreme type of psoriasis, ensuing from its collaboration with Inventiva. This partnership permits the fee to Inventiva of milestone funds based mostly on the achievement of preclinical, scientific, regulatory and industrial targets in addition to royalties on the gross sales of merchandise developed throughout the framework of this partnership.
The Firm has a scientific crew of roughly 70 folks with robust experience in biology, medicinal and computational chemistry, pharmacokinetics and pharmacology in addition to in scientific improvement. As well as, Inventiva has a chemical library of roughly 240,00zero molecules, of which roughly 60% are the property of the Firm, in addition to its personal laboratories and tools.
Inventiva is an organization listed on compartment C of the regulated market of Euronext Paris (Euronext: IVA – ISIN: FR0013233012). ww.inventivapharma.com
Contacts
Inventiva
Frédéric Cren
President and CEO
info@inventivapharma.com
+33 three 80 44 75 00
Brunswick Group
Yannick Tetzlaff / Tristan Roquet Montegon /
Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83
Westwicke, an ICR Firm
Patricia L. Financial institution
Investor relations
patti.bank@westwicke.com
+1 415 513 1284
Warning
This press launch comprises forward-looking statements regarding the World Supply, together with: the completion, timing and measurement of the World Supply, in addition to statements relating to Inventiva's scientific improvement plans, enterprise technique and regulatory, and its anticipated future efficiency. Though the Firm considers that its projections are based mostly on cheap assumptions, these forward-looking statements might be referred to as into query by a sure variety of uncertainties and uncertainties, which might give rise to outcomes considerably completely different from these described, induced or anticipated in stated forward-looking statements. These uncertainties and uncertainties embrace specifically the uncertainties inherent in analysis and improvement, together with these regarding the protection, progress and outcomes of scientific trials in progress or deliberate, together with these of lanifibranor and odiparcil, examinations and authorizations to regulatory authorities such because the FDA and EMA, relating to the Firm's product candidates, the success of in-licensing and out-licensing methods, the Firm's means to proceed to lift funds for its improvement, together with the World Supply envisaged, in addition to these recognized and developed in public paperwork printed by the Firm with the Autorité des Marchés Financiers, specifically within the 2019 Common Registration Doc, to acquire extra data on these components, dangers and uncertainties.
Topic to relevant rules, the Firm makes no dedication to replace or revise the data contained on this press launch. This press launch, and the data it comprises, doesn’t represent a suggestion to promote or subscribe or the solicitation of a purchase order or subscription order for Inventiva shares in any nation. This press launch has been produced in French and English; in case of distinction between the texts, the French model will prevail.
Warnings
This press launch doesn’t represent a suggestion to promote or subscribe, or the solicitation of an order to purchase or subscribe for bizarre shares or ADS in any nation or jurisdiction wherein such a suggestion, solicitation or sale can be unlawful. earlier than registration or any qualification underneath the inventory change rules of such a rustic or jurisdiction.
The distribution of this doc could, in sure nations, be topic to particular rules. Individuals in possession of this doc should inform themselves of any native restrictions and adjust to them.
A French admission prospectus together with (i) the 2019 Common Registration Doc filed with the AMF on June 19, 2020 underneath quantity D. 20-0551, as supplemented by the modification to stated Common Registration Doc which will likely be filed with the AMF on July 10, 2020, and (ii) a Transaction Notice, together with a abstract of the French prospectus, will likely be submitted to the AMF for approval and printed on the AMF web site (www.amf-france.org). As of the submitting of the modification to stated common registration doc with the AMF, copies of the 2019 Common Registration Doc, as amended, will likely be accessible freed from cost on the Firm's registered workplace positioned at 50 rue de Dijon , 21121, Daix – France.
European Financial Space
With regard to every member state of the European Financial Space (every, a “Member State”), no supply to the general public of bizarre shares or ADSs could also be undertaken in any of those member states apart from:
- to any authorized entity which is a “certified investor” as outlined within the Prospectus Laws;
- lower than 150 pure or authorized individuals (apart from “certified buyers” as outlined within the Prospectus Laws), topic to acquiring the prior authorization of the representatives of the Banks for such a suggestion; or
- in different circumstances falling throughout the scope of Article 1 (Four) of the Prospectus Regulation, offered that no supply of bizarre shares and ADS obliges the Firm or any Financial institution to publish a prospectus in accordance with article three of the Prospectus Regulation or in supplementing a prospectus in accordance with Article 23 of the Prospectus Regulation and that every one who initially acquires shares or to whom a suggestion is made is deemed to have represented, acknowledged and agreed with every des Banques and the Firm that it’s a “certified investor” throughout the which means of the Prospectus Laws.
For the needs of this paragraph, the expression “supply to the general public” regarding any bizarre motion and in every of the Member States, is outlined by any communication, in no matter type and by no matter means, and presenting adequate data on the circumstances of the supply and on any bizarre shares and ADS to be provided with the intention to enable an investor to determine to purchase bizarre shares and ADS, and the expression “Prospectus Regulation” means regulation (EU) 2017 / 1129 (as amended).
France
ADS and bizarre shares haven’t been and won’t be provided or bought to the general public in France, and no supply of this prospectus or any advertising and marketing instrument regarding ADS and bizarre shares could also be made accessible or distributed in a manner that may represent, straight or not directly, a suggestion to the general public in France (except public gives outlined in article L. 411-2 1 ° of the Financial and Monetary Code).
Strange shares within the type of ADSs will solely be provided or bought in France, in accordance with article L411-1 of the Financial and Monetary Code to certified buyers (as this time period is outlined in Article 2 (e) of the Regulation (EU) No. 2017/1129 of June 14, 2017, as amended) appearing on personal account and in accordance with articles L.411-1, L.411-2 and D.411-2 to D.411-Four, D.744-1 and D.754-1 and D.764-1 of the Financial and Monetary Code.
This press launch doesn’t represent a promotional communication or a prospectus throughout the which means of the Prospectus Laws.
